Profil bibliographique

Ling-Ming Tseng

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

8Publications signalées

0Citations signalées

0Affiliations récentes

Les domaines associés

HER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyAdvanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Les publications récentes

Accès ouvert 2026 other OpenAlex

Table 1 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

Komal Jhaveri, Sherene Loi, Erika Hamilton, Peter Schmid et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure 3 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

Komal Jhaveri, Sherene Loi, Erika Hamilton, Peter Schmid et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure 2 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

Komal Jhaveri, Sherene Loi, Erika Hamilton, Peter Schmid et autres

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Data 1 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

Komal Jhaveri, Sherene Loi, Erika Hamilton, Peter Schmid et autres

0 citations

Accès ouvert 2026 other OpenAlex

Table 2 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

Komal Jhaveri, Sherene Loi, Erika Hamilton, Peter Schmid et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure 1 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

Komal Jhaveri, Sherene Loi, Erika Hamilton, Peter Schmid et autres

0 citations

Accès ouvert 2026 other OpenAlex

Data from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

Komal Jhaveri, Sherene Loi, Erika Hamilton, Peter Schmid et autres

0 citations

Accès ouvert 2026 other OpenAlex

Table 3 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

Komal Jhaveri, Sherene Loi, Erika Hamilton, Peter Schmid et autres

0 citations

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.